Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EBRAHIM SADEGHI-NAJAFABADI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1205156866
CMS profile
1335690
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,133.40

180 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,133.40 180

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EBRAHIM SADEGHI-NAJAFABADI

NPI 1205156866 · CMS profile ID 1335690

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205156866?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EBRAHIM SADEGHI-NAJAFABADI, NPI 1205156866, CMS profile ID 1335690. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205156866?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). EBRAHIM SADEGHI-NAJAFABADI, NPI 1205156866, CMS profile ID 1335690. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205156866?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
EBRAHIM SADEGHI-NAJAFABADI, NPI 1205156866, CMS profile ID 1335690, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1205156866?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

180 matching records · $3,133.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 180 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 180.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1.6006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920289 CMS
AbbVie Inc. $14.9706/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920281 CMS
AbbVie Inc. $27.9406/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920285 CMS
Amgen Inc. $11.1106/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285005 CMS
Novartis Pharmaceuticals Corporation $9.3606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813220093 CMS
Amgen Inc. $25.7606/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285077 CMS
AbbVie Inc. $25.0206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920277 CMS
Horizon Therapeutics plc $26.4506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797198717 CMS
Lilly USA, LLC $12.0106/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819117373 CMS
PFIZER INC. $26.6505/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832591855 CMS
AbbVie Inc. $12.6505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920273 CMS
GlaxoSmithKline, LLC. $32.4705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802161741 CMS
AbbVie Inc. $2.6705/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920265 CMS
AbbVie Inc. $27.2505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920269 CMS
Amgen Inc. $11.9505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285001 CMS
Amgen Inc. $5.7305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285073 CMS
Horizon Therapeutics plc $5.6505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797198713 CMS
Janssen Biotech, Inc. $3.6505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787983943 CMS
Lilly USA, LLC $21.1105/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819068501 CMS
Novartis Pharmaceuticals Corporation $13.2505/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813220089 CMS
Amgen Inc. $9.0405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284997 CMS
E.R. Squibb & Sons, L.L.C. $23.2705/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783521649 CMS
Horizon Therapeutics plc $29.0305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797198709 CMS
Lilly USA, LLC $19.9905/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819075346 CMS
AbbVie Inc. $21.7205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920257 CMS
AbbVie Inc. $11.6005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920261 CMS
Amgen Inc. $26.2505/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285069 CMS
Radius Health, Inc. $11.7905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830743181 CMS
Amgen Inc. $17.6105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285029 CMS
Amgen Inc. $3.9005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284993 CMS
PFIZER INC. $26.0305/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832561185 CMS
Novartis Pharmaceuticals Corporation $13.6104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813220085 CMS
E.R. Squibb & Sons, L.L.C. $15.0004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783521635 CMS
AbbVie Inc. $24.3404/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920253 CMS
Amgen Inc. $6.8604/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284989 CMS
Amgen Inc. $24.5204/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285025 CMS
PFIZER INC. $26.8304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832576227 CMS
Janssen Biotech, Inc. $21.4904/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787983955 CMS
Novartis Pharmaceuticals Corporation $7.9604/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813220081 CMS
AbbVie Inc. $24.6504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795920249 CMS
Amgen Inc. $9.7604/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284985 CMS
Lilly USA, LLC $13.7704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819085451 CMS
PFIZER INC. $20.7004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832664251 CMS
Amgen Inc. $11.1104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284981 CMS
Janssen Biotech, Inc. $10.1004/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787983947 CMS
Amgen Inc. $22.9204/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285061 CMS
Amgen Inc. $13.6803/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825284977 CMS
Horizon Therapeutics plc $16.8003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797198705 CMS
Amgen Inc. $22.9203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825285057 CMS
Novartis Pharmaceuticals Corporation $10.8303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813220077 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $907.00 41
PY2020 $1,342.29 76
PY2021 $3,133.40 180
PY2022 $4,070.91 184
PY2023 $3,732.24 187
PY2024 $4,248.61 193
PY2025 $3,736.44 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $131,017.69 18
PY2024 Recipient $1,166.82 10
PY2024 Principal investigator $54,881.20 8
PY2023 Recipient $2,216.05 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,670.15 12/04/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527300
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.00 11/14/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170762
Principal investigator 1 ABBVIE INC. $22,784.29 11/05/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522393
Principal investigator 1 ABBVIE INC. $603.45 10/09/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516153
Principal investigator 1 GlaxoSmithKline, LLC. $304.20 09/11/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170778
Principal investigator 1 ABBVIE INC. $2,758.80 08/06/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503541
Principal investigator 1 GlaxoSmithKline, LLC. $3,408.30 07/24/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170766
Principal investigator 1 ABBVIE INC. $17,259.45 07/02/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494515
Principal investigator 1 ABBVIE INC. $75.00 06/03/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202487739
Principal investigator 1 ABBVIE INC. $8,606.25 05/08/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484481
Principal investigator 1 ABBVIE INC. $3,703.54 05/07/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483975
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,080.10 04/04/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185539365
Principal investigator 1 GlaxoSmithKline, LLC. $6,600.00 03/26/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170770
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/26/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170774
Principal investigator 1 GlaxoSmithKline, LLC. $4,987.80 03/21/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CTR
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192170758
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,180.75 03/14/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CENTER
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185539367
Principal investigator 1 ABBVIE INC. $31,224.45 03/13/2025 Non-covered Recipient Entity
UPLAND RHEUMATOLOGY CLINICAL TRIALS
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202463644
Principal investigator 1 GlaxoSmithKline, LLC. $3,581.16 02/26/2025 Non-covered Recipient Entity
UNIVERSITY OF ROCHESTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192170783